2 results
Approved WMORecruiting
Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…
Approved WMOCompleted
The primary objective of this trial is to investigate the proposed beneficial effect of raloxifene as compared to placebo when given for twelve weeks in addition to antipsychotic medication to patients with a psychotic disorder. We expect lower…